2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
Top Cited Papers
Open Access
- 22 August 2019
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatology
- Vol. 71 (10), 1599-1613
- https://doi.org/10.1002/art.41042
Abstract
Objective To update evidence‐based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). Methods We conducted updated systematic literature reviews for 20 clinical questions on pharmacologic treatment addressed in the 2015 guidelines, and for 26 new questions on pharmacologic treatment, treat‐to‐target strategy, and use of imaging. New questions addressed the use of secukinumab, ixekizumab, tofacitinib, tumor necrosis factor inhibitor (TNFi) biosimilars, and biologic tapering/discontinuation, among others. We used the Grading of Recommendations, Assessment, Development and Evaluation methodology to assess the quality of evidence and formulate recommendations and required at least 70% agreement among the voting panel. Results Recommendations for AS and nonradiographic axial SpA are similar. TNFi are recommended over secukinumab or ixekizumab as the first biologic to be used. Secukinumab or ixekizumab is recommended over the use of a second TNFi in patients with primary nonresponse to the first TNFi. TNFi, secukinumab, and ixekizumab are favored over tofacitinib. Co‐administration of low‐dose methotrexate with TNFi is not recommended, nor is a strict treat‐to‐target strategy or discontinuation or tapering of biologics in patients with stable disease. Sulfasalazine is recommended only for persistent peripheral arthritis when TNFi are contraindicated. For patients with unclear disease activity, spine or pelvis magnetic resonance imaging could aid assessment. Routine monitoring of radiographic changes with serial spine radiographs is not recommended. Conclusion These recommendations provide updated guidance regarding use of new medications and imaging of the axial skeleton in the management of AS and nonradiographic axial SpA.Keywords
Funding Information
- Spondylitis Association of America
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (ZIA‐AR‐041153)
This publication has 52 references indexed in Scilit:
- A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS studyAnnals Of The Rheumatic Diseases, 2013
- Secukinumab in the Treatment of Noninfectious Uveitis: Results of Three Randomized, Controlled Clinical TrialsOphthalmology, 2013
- Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up studyBiologics: Targets and Therapy, 2013
- GRADE guidelines: 9. Rating up the quality of evidenceJournal of Clinical Epidemiology, 2011
- Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trialAnnals Of The Rheumatic Diseases, 2011
- Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapyArthritis Research & Therapy, 2010
- Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label studyAnnals Of The Rheumatic Diseases, 2008
- Going from evidence to recommendationsBMJ, 2008
- No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trialAnnals Of The Rheumatic Diseases, 2007
- Evaluation of Diagnostic Criteria for Ankylosing SpondylitisArthritis & Rheumatism, 1984